DFTX: Meets Efficacy Endpoints
Definium Therapeutics announces topline results from its Phase 3 Emerge study, meeting primary and key secondary efficacy endpoints for DT120 in major depressive disorder
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.